Pasar al contenido principal

NUEVAS PERSPECTIVAS EN LAS BASES MOLECULARES Y LOS MECANISMOS FISIOPATOLOGICOS DEL SINDROME DE ELLIS-VAN CREVELD Y OSTEOGENESIS IMPERFECTA

SAF2013-43365-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of a premature stop codon mutation in the PHGDH gene in severe Neu-Laxova syndrome-evidence for phenotypic variability

  • Mattos, Eduardo P.
  • Torreblanca-Zanca, Albertina
  • Ruiz-Pérez, Victor L.
  • Sanseverino, Maria Teresa V.
et al., In some cases Neu-Laxova syndrome (NLS) is linked to serine deficiency due to mutations in the phosphoglycerate dehydrogenase (PHGDH) gene. We describe the prenatal and postnatal findings in a fetus with one of the most severe NLS phenotypes described so far, caused by a homozygous nonsense mutation of PHGDH. Serial ultrasound (US) and pre- and postnatal magnetic resonance imaging (MRI) evaluations were performed. Prenatally, serial US evaluations suggested symmetric growth restriction, microcephaly, hypoplasia of the cerebellar vermis, micrognathia, hydrops, shortened limbs, arthrogryposis, and talipes equinovarus. The prenatal MRI confirmed these findings prompting a diagnosis of NLS. After birth, radiological imaging did not detect any gross bone abnormalities. DNA was extracted from fetal and parental peripheral blood, all coding exons of PHGDH were PCR-amplified and subjected to Sanger sequencing. Sequencing of PHGDH identified a homozygous premature stop codon mutation (c.1297C>T; p.Gln433*) in fetal DNA, both parents (first-cousins) being heterozygotes. Based on previous associations of mutations in this gene with a milder NLS phenotype, as well as cases of serine deficiency, these observations lend further support to a genotype-phenotype correlation between the degree of PHGDH inactivation and disease severity., Grant sponsor: Spanish Ministry of Science and Innovation; Grant number: SAF2013-43365-R; Grant sponsor: The CIBERER Program of Research on Pediatric diseases (ACCI 2012); Grant sponsor: The Brazilian National Council for Research and Development (CNPq); Grant sponsor: Hospital de Clínicas de Porto Alegre (FIPE-HCPA)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GLI1 inactivation is associated with developmental phenotypes overlapping with Ellis–van Creveld syndrome

  • Palencia-Campos, Adrián
  • Ullah, Asmat
  • Nevado, Julian
  • Yildirim, Ruken
  • Unal, Edip
  • Ciorraga, Maria
  • Barruz, Pilar
  • Chico, Lucia
  • Piceci-Sparascio, Francesca
  • Guida, Valentina
  • De Luca, Alessandro
  • Kayserili, Hülya
  • Ullah, Irfan
  • Morales, Aixa V.
  • Ruiz-Pérez, Victor L.
GLI1, GLI2 and GLI3 form a family of transcription factors which regulate development by mediating the action of Hedgehog (Hh) morphogens. Accordingly, inactivating variants in GLI2 and GLI3 are found in several developmental disorders. In contrast, loss-of-function mutations in GLI1 have remained elusive, maintaining enigmatic the role of this gene in the human embryo. We describe eight patients from three independent families having biallelic truncating variants in GLI1 and developmental defects overlapping with Ellis-van Creveld syndrome (EvC), a disease caused by diminished Hh signaling. Two families had mutations in the last exon of the gene and a third family was identified with an N-terminal stop gain variant predicted to be degraded by the NMD-pathway. Analysis of fibroblasts from one of the patients with homozygous C-terminal truncation of GLI1 demonstrated that the corresponding mutant GLI1 protein is fabricated by patient cells and becomes upregulated in response to Hh signaling. However, the transcriptional activity of the truncated GLI1 factor was found to be severely impaired by cell culture and in vivo assays, indicating that the balance between GLI repressors and activators is altered in affected subjects. Consistent with this, reduced expression of the GLI target PTCH1 was observed in patient fibroblasts after chemical induction of the Hh pathway. We conclude that GLI1 inactivation is associated with a phenotypic spectrum extending from isolated postaxial polydactyly to an EvC-like condition., Spanish Ministry of Economy and Competitiveness (SAF2013-43365-R/SAF2016-75434-R to V.L.R.-P. and BFU2014-57494-R to A.V.M.); the Italian Ministry of Health (Ricerca Corrente 2016 and 2017 to A.D.L.); International Research Support Initiative Program (IRSIP), Higher Education Commission (HEC), Islamabad, Pakistan to A.U., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Molecular spectrum and differential diagnosis in patients referred with sporadic or autosomal recessive osteogenesis imperfecta

  • Caparrós-Martín, José A.
  • Aglan, Mona
  • Temtamy, Samia
  • Otaify, Ghada A.
  • Valencia, María
  • Nevado, Julian
  • Vallespin, Elena
  • Pozo, Angela del
  • Prior de Castro, Carmen
  • Calatrava-Ferreras, Lucia
  • Gutiérrez, Pilar
  • Bueno, Ana M.
  • Sagastizabal, Belen
  • Guillén-Navarro, Encarna
  • Ballesta-Martinez, Maria
  • Gonzalez, Vanesa
  • Basaran, Sarenur Y.
  • Buyukoglan, Ruksan
  • Sarikepe, Bilge
  • Espinoza-Valdez, Cecilia
  • Cammarata-Scalisi, Francisco
  • Martinez-Glez, Víctor
  • Heath, Karen E.
  • Lapunzina, Pablo
  • Ruiz-Pérez, Victor L.
[Background]: Osteogenesis imperfecta (OI) is a heterogeneous bone disorder characterized by recurrent fractures. Although most cases of OI have heterozygous mutations in COL1A1 or COL1A2 and show autosomal dominant inheritance, during the last years there has been an explosion in the number of genes responsible for both recessive and dominant forms of this condition. Herein, we have analyzed a cohort of patients with OI, all offspring of unaffected parents, to determine the spectrum of variants accounting for these cases. Twenty patients had nonrelated parents and were sporadic, and 21 were born to consanguineous relationships., [Methods]: Mutation analysis was performed using a next‐generation sequencing gene panel, homozygosity mapping, and whole exome sequencing (WES)., [Results]: Patients offspring of nonconsanguineous parents were mostly identified with COL1A1 or COL1A2 heterozygous changes, although there were also a few cases with IFITM5 and WNT1 heterozygous mutations. Only one sporadic patient was a compound heterozygote for two recessive mutations. Patients offspring of consanguineous parents showed homozygous changes in a variety of genes including CRTAP,FKBP10,LEPRE1,PLOD2,PPIB,SERPINF1,TMEM38B, and WNT1. In addition, two patients born to consanguineous parents were found to have de novo COL1A1 heterozygous mutations demonstrating that causative variants in the collagen I structural genes cannot be overlooked in affected children from consanguineous couples. Further to this, WES analysis in probands lacking mutations in OI genes revealed deleterious variants in SCN9A,NTRK1, and SLC2A2, which are associated with congenital indifference to pain (CIP) and Fanconi–Bickel syndrome (FBS)., [Conclusion]: This work provides useful information for clinical and genetic diagnosis of OI patients with no positive family history of this disease. Our data also indicate that CIP and FBS are conditions to be considered in the differential diagnosis of OI and suggest a positive role of SCN9A and NTRK1 in bone development., Spanish Ministry of Economy and Competitiveness (Grant/Award Number: ‘SAF2013-43365-R’), CIBERER (Grant/Award Number: ‘ER14-PR04-ACCI13-760’)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

FAM46A mutations are responsible for autosomal recessive osteogenesis imperfecta

  • Doyard, Mathilde
  • Bacrot, Séverine
  • Huber, Céline
  • Di Rocco, Maja
  • Goldenberg, Alice
  • Aglan, Mona
  • Brunelle, Perrine
  • Temtamy, Samia
  • Michot, Caroline
  • Otaify, Ghada A.
  • Haudry, Coralie
  • Castanet, Mireille
  • Leroux, Julien
  • Bonnefont, Jean-Paul
  • Munnich, Arnold
  • Baujat, Geneviève
  • Lapunzina, Pablo
  • Monnot, Sophie
  • Ruiz-Pérez, Victor L.
  • Cormier-Daire, Valérie
[Background]: Stüve-Wiedemann syndrome (SWS) is characterised by bowing of the lower limbs, respiratory distress and hyperthermia that are often responsible for early death. Survivors develop progressive scoliosis and spontaneous fractures. We previously identified LIFR mutations in most SWS cases, but absence of LIFR pathogenic changes in five patients led us to perform exome sequencing and to identify homozygosity for a FAM46A mutation in one case [p.Ser205Tyrfs*13]. The follow-up of this case supported a final diagnosis of osteogenesis imperfecta (OI), based on vertebral collapses and blue sclerae., [Methods and results]: This prompted us to screen FAM46A in 25 OI patients with no known mutations. We identified a homozygous deleterious variant in FAM46A in two affected sibs with typical OI [p.His127Arg]. Another homozygous variant, [p.Asp231Gly], also classed as deleterious, was detected in a patient with type III OI of consanguineous parents using homozygosity mapping and exome sequencing. FAM46A is a member of the superfamily of nucleotidyltransferase fold proteins but its exact function is presently unknown. Nevertheless, there are lines of evidence pointing to a relevant role of FAM46A in bone development. By RT-PCR analysis, we detected specific expression of FAM46A in human osteoblasts andinterestingly, a nonsense mutation in Fam46a has been recently identified in an ENU-derived (N-ethyl-N-nitrosourea) mouse model characterised by decreased body length, limb, rib, pelvis, and skull deformities and reduced cortical thickness in long bones., [Conclusion]: We conclude that FAM46A mutations are responsible for a severe form of OI with congenital bowing of the lower limbs and suggest screening this gene in unexplained OI forms., We thank the French Association on Osteogenesis Imperfecta (AOI) for their funding support. Part of this work was financially supported by the Spanish Ministry of Economy and Competitiveness (SAF2013-43365-R/ SAF2016-75434-R to VLRP), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy

  • Estañ, María Cristina
  • Fernández-Núñez, Elisa
  • Zaki, Maha S.
  • Esteban Rodriguez, Isabel
  • Donkervoort, Sandra
  • Hawkins, Cynthia
  • Caparrós-Martín, José A.
  • Saade, Dimah
  • Hu, Ying
  • Bolduc, Véronique
  • Ru-Yui Chao, Katherine
  • Nevado, Julian
  • Lamuedra, Ana
  • Largo, Raquel
  • Herrero-Beaumont, Gabriel
  • Regadera, Javier
  • Hernández-Chico, Concepción
  • Tizzano, Eduardo F.
  • Martinez-Glez, Víctor
  • Carvajal, Jaime J.
  • Zong, Ruiting
  • Nelson, David L.
  • Otaify, Ghada A.
  • Temtamy, Samia
  • Aglan, Mona
  • Issa, Mahmoud
  • Bönnemann, Carsten G.
  • Lapunzina, Pablo
  • Yoon, Grace
  • Ruiz-Pérez, Victor L.
FXR1 is an alternatively spliced gene that encodes RNA binding proteins (FXR1P) involved in muscle development. In contrast to other tissues, cardiac and skeletal muscle express two FXR1P isoforms that incorporate an additional exon-15. We report that recessive mutations in this particular exon of FXR1 cause congenital multi-minicore myopathy in humans and mice. Additionally, we show that while Myf5-dependent depletion of all FXR1P isoforms is neonatal lethal, mice carrying mutations in exon-15 display non-lethal myopathies which vary in severity depending on the specific effect of each mutation on the protein., This work was financially supported by the Spanish Ministry of Economy and Competitiveness (SAF2013-43365-R/SAF2016-75434-R) and CIBERER (ACCI 2017). The work performed at the NIH was supported by intramural funds from the NIH National Institute of Neurological Disorders and Stroke., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Disorganization of chondrocyte columns in the growth plate does not aggravate experimental osteoarthritis in mice

  • Lamuedra, Ana
  • Gratal, Paula
  • Calatrava-Ferreras, Lucia
  • Ruiz-Pérez, Victor L.
  • Largo, Raquel
  • Herrero-Beaumont, Gabriel
Osteoarthritis (OA) is a multifactorial joint disease mainly affecting articular cartilage (AC) with a relevant biomechanical component. During endochondral ossification growth plate (GP) chondrocytes arrange in columns. GPs do not ossify in skeletally mature rodents. In neonatal mice, an altered joint loading induces GP chondrocyte disorganization. We aimed to study whether experimental OA involves GP disorganization in adult mice and to assess if it may have additional detrimental effects on AC damage. Knee OA was induced by destabilization of the medial meniscus (DMM) in wild-type (WT) adult mice, and in Tamoxifen-inducible Ellis-van-Creveld syndrome protein (Evc) knockouts (EvccKO), used as a model of GP disorganization due to Hedgehog signalling disruption. Chondrocyte column arrangement was assessed in the tibial GP and expressed as Column Index (CI). Both DMM-operated WT mice and non-operated-EvccKO showed a decreased CI, indicating GP chondrocyte column disarrangement, although in the latter, it was not associated to AC damage. The most severe GP chondrocyte disorganization occurred in DMM-EvccKO mice, in comparison to the other groups. However, this altered GP structure in DMM-EvccKO mice did not exacerbate AC damage. Further studies are needed to confirm the lack of interference of GP alterations on the analysis of AC employing OA mice., This work was financially supported by grants from the Instituto de Salud Carlos III [PI15/00340, PI16/00065, PI18/00261] to RL and GH-B, and Fondo Europeo de Desarrollo Regional (FEDER) by grants SAF-2013–43365-R and SAF2016-75434-R to VL R-P. AL and PG were funded by Fundación Conchita Rábago., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Blocking chondrocyte hypertrophy in conditional Evc knockout mice does not modify cartilage damage in osteoarthritis

  • Lamuedra, Ana
  • Gratal, Paula
  • Calatrava-Ferreras, Lucia
  • Ruiz-Pérez, Victor L.
  • Palencia-Campos, Adrián
  • Portal-Núñez, Sergio
  • Mediero, Aranzazu
  • Herrero-Beaumont, Gabriel
  • Largo, Raquel
Chondrocytes in osteoarthritic (OA) cartilage acquire a hypertrophic-like phenotype, where Hedgehog (Hh) signaling is pivotal. Hh overexpression causes OA-like cartilage lesions, whereas its downregulation prevents articular destruction in mouse models. Mutations in EVC and EVC2 genes disrupt Hh signaling, and are responsible for the Ellis-van Creveld syndrome skeletal dysplasia. Since Ellis-van Creveld syndrome protein (Evc) deletion is expected to hamper Hh target gene expression we hypothesized that it would also prevent OA progression avoiding chondrocyte hypertrophy. Our aim was to study Evc as a new therapeutic target in OA, and whether Evc deletion restrains chondrocyte hypertrophy and prevents joint damage in an Evc tamoxifen induced knockout (EvccKO) model of OA. For this purpose, OA was induced by surgical knee destabilization in wild-type (WT) and EvccKO adult mice, and healthy WT mice were used as controls (n = 10 knees/group). Hypertrophic markers and Hh genes were measured by qRT-PCR, and metalloproteinases (MMP) levels assessed by western blot. Human OA chondrocytes and cartilage samples were obtained from patients undergoing knee joint replacement surgery. Cyclopamine (CPA) was used for Hh pharmacological inhibition and IL-1 beta as an inflammatory insult. Our results showed that tamoxifen induced inactivation of Evc inhibited Hh overexpression and partially prevented chondrocyte hypertrophy during OA, although it did not ameliorate cartilage damage in DMM-EvccKO mice. Hh pathway inhibition did not modify the expression of proinflammatory mediators induced by IL-1 beta in human OA chondrocytes in culture. We found that hypertrophic—IHH—and inflammatory—COX-2—markers co-localized in OA cartilage samples. We concluded that tamoxifen induced inactivation of Evc partially prevented chondrocyte hypertrophy in DMM-EvccKO mice, but it did not ameliorate cartilage damage. Overall, our results suggest that chondrocyte hypertrophy per se is not a pathogenic event in the progression of OA., This work was financially supported by grants from the Instituto de Salud Carlos III [PI20/00349, PI16/00065, PI18/00261] and Fondo Europeo de Desarrollo Regional (FEDER); and by the Spanish Ministry of Science and Innovatin (MICINN) [SAF-2013-43365-R and SAF2016-75434-R] to VLR-P. AL and PG were funded by Fundación Conchita Rábago.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Variant characterisation and clinical profile in a large cohort of patients with Ellis-van Creveld syndrome and a family with Weyers acrofacial dysostosis

  • Altunoglu, Umut
  • Palencia-Campos, Adrián
  • Güneş, Nilay
  • Tutku Turgut, Gozde
  • Nevado, Julian
  • Lapunzina, Pablo
  • Valencia, María
  • Iturrate, Asier
  • Otaify, Ghada A.
  • Elhossini, Rasha
  • Ashour, Adel
  • Amin, Asmaa K.
  • Elnahas, Rania F.
  • Fernandez-Nuñez, Elisa
  • Flores, Carmen-Lisset
  • Arias, Pedro
  • Tenorio, Jair
  • Chamorro Fernández, Carlos Israel
  • Güven, Yeliz
  • Özsu, Elif
  • Selver Eklioğlu, Beray
  • Ibarra-Ramirez, Marisol
  • Rode Diness, Birgitte
  • Burnyte, Birute
  • Ajmi, Houda
  • Yükse, Zafer
  • Yildirim, Ruken
  • Unal, Edip
  • Abdalla, Ebtesam
  • Aglan, Mona
  • Kayserili, Hülya
  • Tuysuz, Beyhan
  • Ruiz-Pérez, Victor L.
[Background]: Ellis-van Creveld syndrome (EvC) is a recessive disorder characterised by acromesomelic limb shortening, postaxial polydactyly, nail-teeth dysplasia and congenital cardiac defects, primarily caused by pathogenic variants in EVC or EVC2. Weyers acrofacial dysostosis (WAD) is an ultra-rare dominant condition allelic to EvC. The present work aimed to enhance current knowledge on the clinical manifestations of EvC and WAD and broaden their mutational spectrum., [Methods]: We conducted molecular studies in 46 individuals from 43 unrelated families with a preliminary clinical diagnosis of EvC and 3 affected individuals from a family with WAD and retrospectively analysed clinical data. The deleterious effect of selected variants of uncertain significance was evaluated by cellular assays., [Main results]: We identified pathogenic variants in EVC/EVC2 in affected individuals from 41 of the 43 families with EvC. Patients from each of the two remaining families were found with a homozygous splicing variant in WDR35 and a de novo heterozygous frameshift variant in GLI3, respectively. The phenotype of these patients showed a remarkable overlap with EvC. A novel EVC2 C-terminal truncating variant was identified in the family with WAD. Deep phenotyping of the cohort recapitulated ‘classical EvC findings’ in the literature and highlighted findings previously undescribed or rarely described as part of EvC., [Conclusions]: This study presents the largest cohort of living patients with EvC to date, contributing to better understanding of the full clinical spectrum of EvC. We also provide comprehensive information on the EVC/EVC2 mutational landscape and add GLI3 to the list of genes associated with EvC-like phenotypes., This work was funded by the Spanish Ministry of Economy and Competitiveness (SAF2010-17901, SAF2013-43365-R, SAF2016-75434-R, PID2019-105620RB-I00/AEI/10.13039/501100011033) and FEDER funds through ISCIII grant PI20/01053 and PMP21/00063/Instituto de Salud Carlos III., Peer reviewed